Results 141 to 150 of about 29,283 (270)

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1962-1973, 15 October 2026.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

Translating ctDNA into cutaneous melanoma care: An international expert survey

BACKGROUND: Circulating tumor DNA (ctDNA) is a promising biomarker in melanoma, with higher sensitivity for tumor burden detection than conventional diagnostics. While well established in research, clinical routine implementation remains pending.
Johnson, Douglas B, Kandolf, Lidija, Corrie, Pippa, Rizos, Helen, Lee, Rebecca, Malvehy, Josep, Fekade, Nathan, Raabe, Katharina, Kirkwood, John M, Zell, Tim, Mohr, Peter, Smit, Daniel J, Svane, Inge Marie, Hauschild, Axel, Patel, Sapna P, Rünger, Alessandra, Schadendorf, Dirk, Pantel, Klaus, Eggermont, Alexander, Jalving, Mathilde, Amaral, Teresa, Robert, Caroline, Sondak, Vernon K, Long, Georgina V, Hassel, Jessica C, Kött, Julian, Melanoma World Society Study Group, Wainstein, Alberto, Dummer, Reinhard, Lebbé, Celeste, Heidrich, Isabel, MS Hematologie, Adam, Laura, Gebhardt, Christoffer, Zager, Jonathan S, Guo, Jun, Geidel, Glenn, Ascierto, Paolo A, Mangana, Joanna, Lorigan, Paul   +39 more
core  

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

International Journal of Cancer, Volume 159, Issue 8, Page 2075-2083, 15 October 2026.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut   +9 more
wiley   +1 more source

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

International Journal of Cancer, Volume 159, Issue 8, Page 1873-1883, 15 October 2026.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington, Maria Raitses‐Gurevich, Giulio Innamorati, Phil A. Hart, Thomas M. Wilkie, Noam Tau, Dana Brin, Doron Yablecovitch, Ido Laish, Dove Keith, Kurt Giles, Jennifer B. Permuth, Diane M. Simeone, George Zogopoulos, Randall E. Brand, John J. Graff, Julie Earl, On behalf of the PRECEDE Consortium, Nikhil Agarwal, Laufey Amundadottir, Michelle Anderson, Ajay Bansal, Todd Bauer, Georg Beyer, Yan Bi, Erkut Borazanci, Randy Brand, Teri Brentnall, Carol Burke, Darren Carpizo, Saurabh Chawla, Daniel Chung, Sourat Darabi, Michael Demeure, Timothy Donahue, Julie Earl, Whitney Espinel, James Farrell, Vigdís Fjóla Stefánsdóttir, Jared Forrester, Eitan Friedman, Paul Franklin, Srinivas Gaddam, Ana García García de Paredes, Steven Gallinger, Talia Golan, Ora Gordon, Robert Grant, William Greenhalf, Eli Marie Grindedal, Aaron Grossberg, Brenda Hafers, Heather Hannon, Sigurdís Haraldsdóttir, Stefán Haraldsson, Peter Hegyi, Melissa Hogg, Amy de Haar‐Holleman, Susan Hong, Greg Idos, Edward Kim, Fay Kastrinos, Bryson Katona, Vivek Kaul, Derk Klatte, Kelsey Klute, Kimberly Ku, Sonia Kupfer, Rich Kwon, Rosario Ligresti, James James Lin, Wei‐Chih (David) Liao, Aimee Lucas, Nipun Merchant, Andrew Metz, Whitney Maxwell, James McLoughlin, Sodech Miclette, Xavier Molero, Leticia Moreira, Takuji Okusaka Chigusa Morizane, Joanne Ngeow, Salvatore Paiella, Jennifer Permuth, Maricel Purcell, Joshua Raff, Vineet Rolston, Intan Schrader, Rosie Sears, Yan‐Shen Shan, Diane Simeone, Jens Siveke, Brett Sheppard, Tyler Stevens, Elena Stoffel, Dan Sussman, Margaret Tempero, Jose Trevino, Jennifer Valerin, Eva Vaquero, Ray Wadlow, Garrett Ward, David Weinberg, Ronald Wolf, Dana Zakalik, George Zogopoulos   +105 more
wiley   +1 more source

Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques

Cancer Management and Research
Wenlong Qi,1 Lin Tian,2 Jianan Xu,2 Zhenyu Li,2 Tan Wang2 1Changchun University of Traditional Chinese Medicine, Changchun, Jilin, 130000, People’s Republic of China; 2Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun,
Qi W, Tian L, Xu J, Li Z, Wang T
doaj  

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients

International Journal of Cancer, Volume 159, Issue 7, Page 1829-1843, 1 October 2026.
Long non‐coding RNAs (lncRNAs) signatures are promising cancer biomarkers, since their dysregulation in tumors is reflected in body fluids. In this study, next‐generation sequencing, bioinformatics, and gene expression data were combined to investigate an lncRNA signature linked specifically to the cancer‐promoting YAP in several cancer types ...
Fabian Rose, Nada El‐Ekiaby, Lilija Wehling, Sofia Maria Elisabeth Weiler, Jennifer Schmitt, Marcell Tóth, Fabiola Pedrini, Amruta Damle‐Vartak, Carsten Sticht, Rossella Pellegrino, Injie Omar Fawzy, Merna Hatem Mohamed Hamad, Mohamed Negm, Dina Omar, Hossam Eldeen Soliman, Gamal Esmat, Thomas Longerich, Thomas Illig, Bruno Christian Köhler, Anna Saborowski, Heike Bantel, Arndt Vogel, Peter Schirmacher, Ahmed Ihab Abdelaziz, Kai Breuhahn   +24 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1368-1381, September 2026.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Multidisciplinary Treatment for Esophagogastric Junction Cancer From a Dutch Perspective

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1404-1418, September 2026.
ABSTRACT Esophagogastric junction (EGJ) cancer is an increasing health burden worldwide. Over the past decade, significant advancements in centralization, multimodal treatment strategies, as well as the widespread adoption of minimally invasive surgical techniques, have led to marked improvements in perioperative outcomes and overall survival of EGJ ...
Hidde C. G. Overtoom, Suzanne S. Gisbertz   +1 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

The utility of ctDNA in rectal cancer

The Oncologist
Gagandeep Brar, Pashtoon Murtaza Kasi
openaire   +2 more sources